Refining Tamoxifen Dose for Premenopausal Breast Cancer Risk Reduction (RENAISSANCE): A Phase II Single Arm Trial

Sponsor:

National Cancer Institute

Sponsor Study ID:

INT23-14-01

CTO #:

103965

NCT Number:

NCT06184750

Phase:

II

Protocol Type:

Treatment

Age Group:

Adults

Disease Sites:

Breast

Study Objectives:

The primary objective of this study is to evaluate whether the overall proportion of premenopausal tamoxifen responders (defined by absolute dense area reduction on mammogram of >10%) can be increased through a strategy of within-individual dose escalation among non-responders from 5 mg per day to 10 mg per day.

eConsent:

Not available

Study Documents:

Open Study Documents
(MUSC NetID required for document access)